Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial
Source: View publication →
The phase I/II F-SHARP trial demonstrated that dose-escalated focal salvage high-dose-rate brachytherapy for intraprostatic radiorecurrence is safe with minimal severe toxicity, and identified genomic classifier scoring as a strong prognostic tool for predicting subsequent recurrence.
Key Findings
Study Design
Study Limitations
Clinical Significance
Salvage local therapy for locally recurrent prostate cancer after primary radiotherapy has historically been fraught with prohibitively high rates of severe genitourinary and gastrointestinal toxicities. The F-SHARP trial establishes that modern, dose-escalated focal salvage HDR brachytherapy—which leverages advanced imaging to target only the recurrent tumor rather than the whole gland—has an excellent safety profile (0% acute, 3.2% late grade 3 toxicity). Furthermore, it pioneers the use of a transcriptomic genomic classifier in the radiorecurrent setting. By demonstrating that patients with high genomic risk scores (>0.85) uniformly recur, the study suggests that genomic profiling could be used to spare systemic-risk patients from futile local-only salvage, and instead identify candidates for treatment intensification.
Historical Context
Historically, intraprostatic recurrence following definitive radiation therapy left patients with grim therapeutic choices. Whole-gland salvage options—such as salvage radical prostatectomy, cryotherapy, or whole-gland brachytherapy—carried substantial morbidity, including high rates of incontinence, strictures, and rectourethral fistulas. Consequently, many patients were relegated to lifelong palliative androgen deprivation therapy. Over the last decade, advances in multiparametric MRI and PSMA PET have allowed precise localization of recurrent disease, fueling a paradigm shift toward focal salvage. The F-SHARP trial builds upon this technological evolution by prospectively validating a highly conformal, dose-escalated focal HDR brachytherapy approach. Importantly, it is one of the first trials to integrate a commercial genomic classifier (traditionally validated for primary, untreated prostate cancer) into the salvage setting, addressing a critical need for biomarker-driven patient selection.
Guided Discussion
High-yield insights from every perspective
What is the radiobiologic rationale for using High-Dose-Rate (HDR) brachytherapy as a salvage treatment for prostate cancer that has recurred after initial external beam radiation therapy?
Key Response
HDR brachytherapy exploits the low alpha/beta ratio of prostate cancer by delivering very high doses per fraction, maximizing tumor cell kill. Concurrently, the rapid dose fall-off of the radioactive source minimizes collateral damage to adjacent previously irradiated normal tissues like the rectum and bladder, making it ideal for salvage therapy.
When evaluating a patient with biochemical recurrence after primary radiotherapy for prostate cancer, what diagnostic modalities are essential to confirm isolated intraprostatic recurrence before offering focal salvage brachytherapy like in the F-SHARP trial?
Key Response
Advanced molecular imaging, typically PSMA PET/CT, is critical to rule out regional or distant metastatic disease. Subsequently, a multiparametric MRI followed by an MRI-targeted biopsy of the prostate is necessary to definitively confirm local recurrence and precisely map the specific intraprostatic lesion for focal therapy planning.
The F-SHARP trial utilizes a genomic classifier to risk-stratify radiorecurrent prostate cancer. How should a high-risk genomic score influence the clinical decision to proceed with focal salvage brachytherapy versus initiating systemic therapy?
Key Response
A high-risk genomic classifier score indicates aggressive tumor biology with a high propensity for micrometastatic disease not visible on imaging. In such cases, isolated focal salvage may be insufficient for long-term disease control, suggesting these patients might benefit more from early intensification with systemic androgen receptor pathway inhibitors rather than solely pursuing local focal therapy.
Historically, whole-gland salvage therapies carried high rates of severe genitourinary toxicity. How do the toxicity profile and efficacy of dose-escalated focal salvage HDR brachytherapy from the F-SHARP trial change our counseling for patients who previously would have been relegated to lifelong palliative ADT?
Key Response
The F-SHARP trial demonstrates that focal salvage significantly reduces grade 3+ GU/GI toxicity compared to historical whole-gland salvage. This paradigm shift allows attendings to offer a potentially curative, well-tolerated local option rather than defaulting to the significant metabolic and quality-of-life burdens of lifelong ADT, provided the recurrence is unifocal and the genomic risk is favorable.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In designing a Phase I/II trial evaluating both a novel focal HDR dose-escalation schedule and a prognostic biomarker (genomic classifier), what are the statistical challenges in powering the study to evaluate both dose-limiting toxicities and the interaction between genomic risk and recurrence-free survival?
Key Response
Phase I dose-finding typically utilizes small cohorts (e.g., 3+3 or Continual Reassessment Method) focusing on acute toxicity, which severely limits sample size. Evaluating a biomarker's prognostic utility requires a much larger sample to achieve adequate statistical power for time-to-event endpoints. Thus, the Phase II expansion cohort must be rigorously powered to detect hazard ratio differences stratified by the genomic classifier, independent of the initial toxicity endpoints.
As a peer reviewer evaluating the F-SHARP trial, what primary threats to internal validity would you scrutinize regarding the definition of 'biochemical recurrence' post-focal salvage, considering the established challenges of applying traditional criteria to focal therapy?
Key Response
The Phoenix criteria (nadir + 2 ng/mL) was designed for primary whole-gland radiotherapy. Its application to focal salvage is highly problematic because untreated benign prostatic tissue continues to produce PSA. A stringent reviewer would look for protocol-defined biopsy mandates or specific PSA kinetics to accurately differentiate true treatment failure from benign PSA bounce or out-of-field intraprostatic progression.
Given the findings of the F-SHARP trial, should current AUA/ASTRO guidelines for radiorecurrent prostate cancer be updated to formally recommend genomic classifier testing prior to selecting patients for local focal salvage therapy?
Key Response
Current AUA/ASTRO guidelines recommend restaging (with PSMA PET) and prostate biopsy for suspected radiorecurrence but do not uniformly mandate genomic classifier testing for salvage patient selection. If F-SHARP strongly confirms the prognostic utility of genomic classifiers in identifying patients who will fail local salvage, guidelines should be updated to include GC testing as a formal recommendation to help triage patients between local salvage versus immediate systemic therapy.
Clinical Landscape
Noteworthy Related Trials
MSKCC Focal Salvage HDR Trial
Tested
Focal salvage high-dose-rate (HDR) brachytherapy
Population
Men with MRI-directed biopsy-proven locally recurrent prostate cancer after definitive radiation
Comparator
Historical whole-gland salvage outcomes
Endpoint
Biochemical control and treatment-related toxicity
RTOG 0526
Tested
Whole-gland salvage low-dose-rate (LDR) brachytherapy
Population
Patients with locally recurrent prostate cancer post-external beam radiotherapy
Comparator
Single-arm trial without direct comparator
Endpoint
Late grade 3 or higher gastrointestinal and genitourinary toxicity
SAKK 09/10 Decipher Substudy
Tested
Genomic classifier (Decipher) risk stratification for salvage radiotherapy
Population
Prostate cancer patients experiencing biochemical recurrence after initial local therapy
Comparator
Standard clinical-pathological risk stratification
Endpoint
Freedom from biochemical progression (FFBP)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis